Curi RMB Capital LLC Sells 18,973 Shares of Pfizer Inc. $PFE

Key Points

• Curi RMB Capital LLC sold 18,973 shares of Pfizer Inc., reducing its holdings by 50.2% and bringing its stake to approximately $477,000.
• Analyst ratings for Pfizer show a mix of sentiments, with two analysts rating it as a Strong Buy and an average target price of $28.12, while others have varied views with ratings from Hold to Sell.
• Pfizer reported $0.78 earnings per share (EPS) for the recent quarter, exceeding estimates of $0.58, along with a revenue of $14.65 billion, indicating a 10.3% year-over-year increase.

Curi RMB Capital LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 50.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,833 shares of the biopharmaceutical company's stock after selling 18,973 shares during the quarter. Curi RMB Capital LLC's holdings in Pfizer were worth $477,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in Pfizer by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock valued at $13,257,004,000 after buying an additional 4,629,976 shares in the last quarter. Northern Trust Corp grew its holdings in Pfizer by 6.8% during the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company's stock valued at $1,579,340,000 after buying an additional 3,943,397 shares in the last quarter. Amundi increased its holdings in shares of Pfizer by 43.4% in the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock worth $1,265,277,000 after purchasing an additional 15,758,846 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Pfizer by 3.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company's stock worth $1,045,351,000 after purchasing an additional 1,333,740 shares during the period. Finally, Invesco Ltd. increased its holdings in shares of Pfizer by 2.8% in the first quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock worth $767,709,000 after purchasing an additional 838,198 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Bank of America upped their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Citigroup upped their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Jefferies Financial Group upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. Berenberg Bank decreased their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Finally, HSBC decreased their price target on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Pfizer presently has an average rating of "Hold" and an average target price of $28.12.

Pfizer Stock Up 1.3%

Shares of PFE opened at $24.86 on Friday. The firm has a market cap of $141.31 billion, a P/E ratio of 13.22, a P/E/G ratio of 0.88 and a beta of 0.55. The stock has a 50 day simple moving average of $24.85 and a two-hundred day simple moving average of $24.35. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. During the same period last year, the firm earned $0.60 earnings per share. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer's dividend payout ratio (DPR) is 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.